---
title: "Ocrevus (ocrelizumab) in multiple sclerosis: Indication questions"
description: "Indication questions on Ocrevus (ocrelizumab) in multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names. Questions: What are Ocrevus and Ocrevus Zunovo approved to treat? What is the generic name for Ocrevus and Ocrevus Zunovo? 2 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/indication"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ocrevus (ocrelizumab) in multiple sclerosis: Indication questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Ocrevus](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf), [Ocrevus Zunovo](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf)

Questions that apply to every indication of Ocrevus are on [Ocrevus (ocrelizumab), all indications](https://www.evicenter.com/medical-information/ocrevus).

## Indication

<a id="ocrevus-indication"></a>

### What are Ocrevus and Ocrevus Zunovo approved to treat?

> “OCREVUS and OCREVUS ZUNOVO are indicated for the treatment of:
>
> Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
> Primary progressive MS, in adults.”

Source: [OCREVUS: Important Safety Information for HCPs, captured 2026-11-12](https://www.ocrevus-hcp.com/safety.html#:~:text=OCREVUS%20and%20OCREVUS%20ZUNOVO%20are,Primary%20progressive%20MS%2C%20in%20adults.)

Note: OCREVUS (intravenous) is also indicated for relapsing-remitting MS in pediatric patients 10 years of age and older who weigh 25 kg or more.

## Drug names

<a id="ocrevus-generic-name"></a>

### What is the generic name for Ocrevus and Ocrevus Zunovo?

> “OCREVUS<sup>®</sup> (ocrelizumab) injection, for intravenous use 
> Initial U.S. Approval: 2017”

Source: [OCREVUS: OCREVUS \[IV\], page 1, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_prescribing.pdf#page=1)

> “OCREVUS ZUNOVO<sup>®</sup> (ocrelizumab and hyaluronidase-ocsq) injection, 
> for subcutaneous use 
> Initial U.S. Approval: 2024”

Source: [OCREVUS: OCREVUS ZUNOVO, page 1, captured 2026-11-12](https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf#page=1)

Note: Both passages are the title lines of the Prescribing Information: the first for OCREVUS, the second for OCREVUS ZUNOVO.

## Related pages
- [Medical information: Ocrevus (ocrelizumab): Multiple sclerosis](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis)
- [Pharmacology](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/ocrevus--multiple-sclerosis/storage-and-supply)
